Status:
WITHDRAWN
Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)
Lead Sponsor:
Abderrahmane Mami Hospital
Collaborating Sponsors:
Eshmoun Clinical Research Center
Dacima Consulting
Conditions:
Patients With COVID19
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The study will assess the number of patients who become asymptomatic from clinical signs of COVID19 and will assess the efficacy of Hydroxychloroquine (HCQ) and Azithromycine effects on paucisymptomat...
Eligibility Criteria
Inclusion
- confirmed COVID19 (+)
- Qt\<500ms
- no severity criteria
- pauci-symptomatique patients
- signed consent form
Exclusion
- no confirmed patient COVID19
- severity criteria
- known allegies to macrolides and HCQ
- Treated with HCQ within 1 month prior to inclusion
- hepatitis insufficiency
- Renal insufficiency
- treatment no indicated with azithro and HCQ
- hypovolemia
- complete brach block
- retinopathia
- psoriasis
- pregnancy or breastfeeding
Key Trial Info
Start Date :
May 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 15 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04351919
Start Date
May 5 2020
End Date
July 15 2020
Last Update
August 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana
Tunis, Tunisia